AtaiBeckley Inc. (ATAI)
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has reported its fourth quarter and full-year 2025 financial results, highlighting progress across several clinical programs targeting mental health disorders and outlining upcoming milestones for its pipeline. The clinical-stage biotechnology company said it remains on track to initiate a Phase 3 pivotal program for BPL-003, its mebufotenin benzoate nasal spray for treatment-resistant depression (TRD), in the second quarter of 2026.
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing
The FDA has supported the Phase 3 design for BPL-003, an intranasal psychedelic-derived therapy for treatment-resistant depression AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC), a clinical-stage biotechnology company focused on mental health treatments, has received backing from US regulators to advance its BPL-003 drug candidate into Phase 3 clinical trials for treatment-resistant depression, a condition affecting millions of patients for whom standard antidepressants have failed. The company said a formal end-of-phase 2 meeting with the Food and Drug Administration (FDA) concluded successfully, with the regulator indicating support for its proposed pivotal trial programme and providing constructive feedback on study design, safety database requirements and other key components.
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has reported positive topline results from an exploratory Phase 2a trial evaluating its oral R-MDMA candidate, EMP-01, in adults with social anxiety disorder (SAD), with the study meeting its primary safety objective and showing encouraging efficacy signals. The clinical-stage biotechnology company said the randomized, double-blind, placebo-controlled study enrolled 71 adults with moderate-to-severe SAD across seven sites in the United Kingdom.
AtaiBeckley names Michael Faerm as finance chief
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25 years of experience spanning life sciences firms, equity research and investment banking.
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
AtaiBeckley shares clinical and preclinical data at ACNP Annual Meeting
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The Bahamas, where the company presented two scientific posters and delivered a Hot Topic Presentation. The clinical-stage biotechnology company said the presentations included new clinical and preclinical data related to its mental health development programs.
New Strong Sell Stocks for Jan. 13
ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
AtaiBeckley issues 2026 outlook, flags multiple clinical milestones
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has outlined its outlook for 2026, highlighting anticipated clinical milestones and recent corporate developments ahead of its participation in the JP Morgan 44th Annual Healthcare Conference in San Francisco later this month. The clinical-stage biotechnology company said it enters 2026 following the completion of the strategic combination of atai Life Sciences and Beckley Psytech, and its recent redomiciliation to the United States.
AtaiBeckley completes redomiciliation from Netherlands to US
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4.
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3
AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD) and other mental health conditions. During the quarter, the company's lead candidate BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray, was granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for TRD.
